ivosidenib — CareFirst (Caremark)

Initial criteria

• Subsequent treatment of unresectable, resected gross residual (R2), locally advanced, or metastatic cholangiocarcinoma as a single agent in members with an IDH1 mutation

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on the current regimen

Approval duration

12 months